Surveillance, Patient Resources, and Financial Support

This closing segment follows the patient into surveillance as he and his wife worry about recurrence. The faculty stress setting expectations early, since bladder cancer tends to recur and close follow-up helps catch recurrences while all treatment options remain available. Surveillance relies on regular cystoscopy that becomes less frequent over time, with imaging reserved for specific clinical concerns in low-grade disease. To help patients engage in their care, the panel encourages patients and family members to attend pretreatment education sessions covering treatment, side effects, and how to reach the care team. The faculty recommend guideline-based information from the American Urological Association (AUA) and the National Comprehensive Cancer Network (NCCN), along with Bladder Cancer Advocacy Network (BCAN) materials. On cost, they acknowledge the financial toxicity of newer therapies. They advise nurses and advanced practice providers to explore local hospital assistance programs and insurance arrangements, and to connect patients with advocacy groups and manufacturer support programs.